MPA
MCID: MCR088
MIFTS: 51

Microscopic Polyangiitis (MPA)

Categories: Bone diseases, Cardiovascular diseases, Nephrological diseases, Neuronal diseases, Rare diseases, Respiratory diseases

Aliases & Classifications for Microscopic Polyangiitis

MalaCards integrated aliases for Microscopic Polyangiitis:

Name: Microscopic Polyangiitis 52 58 36 17 32
Microscopic Polyarteritis 58 71
Micropolyangiitis 58
Mpa 58

Characteristics:

Orphanet epidemiological data:

58
microscopic polyangiitis
Inheritance: Not applicable; Prevalence: 1-9/100000 (Europe),1-9/1000000 (Germany),1-9/1000000 (Norway),1-9/100000 (United Kingdom),1-9/100000 (Germany),1-9/100000 (Australia),1-9/100000 (Japan),1-9/100000 (Kuwait),1-9/1000000 (Canada),1-9/100000 (Greece),1-9/1000000 (Lithuania),1-9/100000 (Sweden); Age of onset: Adult; Age of death: adult;

Classifications:

Orphanet: 58  
Rare neurological diseases
Rare circulatory system diseases
Rare renal diseases
Rare respiratory diseases
Rare systemic and rhumatological diseases


Summaries for Microscopic Polyangiitis

KEGG : 36 Microscopic polyangiitis (MPA) is an idiopathic autoimmune disease characterized by systemic vasculitis. MPA predominantly affects small-calibre blood vessels and is associated with the presence of antineutrophil cytoplasmic autoantibodies (ANCA). The association with ANCAs originally defined the group of ANCA-associated vasculitides, comprising granulomatosis with polyangitis (GPA, formerly known as Wegener granulomatosis) [DS:H01655], microscopic polyangiitis (MPA), and eosinophilic granulomatosis with polyangiitis (EGPA, formerly known as Churg-Strauss syndrome) [DS:H01468], which have different frequencies of ANCA-positivity. ANCA in MPA are predominantly directed against myeloperoxidase (MPO-ANCA) but may, in a minority of patients, be directed against proteinase 3 (PR3-ANCA). Not all patients, however, have ANCA. MPA is clinically characterized by small-vessel vasculitis primarily affecting the kidneys and the lungs but other organs may be involved as well. Renal involvement, which can be the only manifestation, is clinically apparent as rapidly progressive glomerulonephritis and histopathologically as pauci-immune necrotizing and crescentic glomerulonephritis. Diagnosis is mainly established by clinical manifestations, computed tomography (TC), ANCA antibody detection, and renal and pulmonary biopsy. The introduction of aggressive immunosuppressive treatment has substantially improved the prognosis. The standardized therapeutic regimen is based on cyclophosphamide and corticosteroids. Using this regimen, remission can be achieved in most of the patients. Rituximab may represent an important alternative to cyclophosphamide for patients who may not respond adequately to antimetabolite therapies.

MalaCards based summary : Microscopic Polyangiitis, also known as microscopic polyarteritis, is related to anca-associated vasculitis and vasculitis. An important gene associated with Microscopic Polyangiitis is MPO (Myeloperoxidase), and among its related pathways/superpathways are NF-kappaB Signaling and Toxoplasmosis. The drugs Methotrexate and leucovorin have been mentioned in the context of this disorder. Affiliated tissues include neutrophil, lung and kidney, and related phenotypes are renal insufficiency and fever

NIH Rare Diseases : 52 Microscopic polyangiitis (MPA) is a disorder that causes blood vessel inflammation (vasculitis ), which can lead to organ damage. The kidneys, lungs, nerves, skin, and joints are the most commonly affected areas of the body. MPA is diagnosed in people of all ages, all ethnicities, and both genders. The cause of this disorder is unknown.

Wikipedia : 74 Microscopic polyangiitis is an ill-defined autoimmune disease characterized by a systemic, pauci-immune,... more...

Related Diseases for Microscopic Polyangiitis

Diseases related to Microscopic Polyangiitis via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 463)
# Related Disease Score Top Affiliating Genes
1 anca-associated vasculitis 32.7 MPO CTLA4
2 vasculitis 31.4 TNF MPO CX3CL1 CTLA4
3 polyarteritis nodosa 31.2 MPO HLA-DRB1
4 mononeuritis multiplex 30.9 TNF MPO
5 churg-strauss syndrome 30.7 TNF MPO HLA-DRB1
6 granulomatosis with polyangiitis 30.6 TNF MPO CTLA4
7 mononeuropathy 30.4 TNF MPO
8 infective endocarditis 30.1 TNF FCGR2A
9 scleritis 30.1 TNF CTLA4
10 pleurisy 30.0 TNF MPO
11 exanthem 30.0 TNF MPO CTLA4
12 graft-versus-host disease 30.0 TNF HLA-DRB1
13 aortitis 29.9 TNF MPO
14 granulocytopenia 29.9 TNF MPO
15 thyroiditis 29.9 TNF CTLA4
16 hypersensitivity vasculitis 29.9 TNF MPO
17 chickenpox 29.9 TNF CTLA4
18 pneumoconiosis 29.9 TNF HLA-DRB1
19 pharyngitis 29.8 TNF HLA-DRB1
20 nephrosclerosis 29.8 TNF MPO
21 coronary aneurysm 29.8 TNF FCGR2A
22 appendicitis 29.8 TNF MPO
23 thrombocytopenic purpura, autoimmune 29.8 HLA-DRB1 FCGR2A
24 cryoglobulinemia 29.8 TNF HLA-DRB1
25 mixed connective tissue disease 29.8 TNF HLA-DRB1
26 cryptococcosis 29.8 TNF FCGR2A
27 skin sarcoidosis 29.7 TNF CTLA4
28 takayasu arteritis 29.7 TNF HLA-DRB1 FCGR2A
29 autoimmune disease 29.6 TNF HLA-DRB1 FCGR2A CTLA4
30 primary biliary cirrhosis 29.6 TNF HLA-DRB1 CTLA4
31 sclerosing cholangitis 29.5 TNF MPO HLA-DRB1
32 goodpasture syndrome 29.5 MPO HLA-DRB1 FCGR2A
33 membranous nephropathy 29.4 TNF MPO
34 conjunctivitis 29.3 TNF MPO
35 temporal arteritis 29.3 TNF MPO HLA-DRB1 CTLA4
36 bronchiolitis obliterans 29.3 TNF MPO CTLA4
37 juvenile rheumatoid arthritis 29.2 TNF HLA-DRB1 CTLA4
38 autoimmune hepatitis 29.2 TNF HLA-DRB1 CTLA4
39 hashimoto thyroiditis 29.2 TNF HLA-DRB1 CTLA4
40 rheumatoid vasculitis 29.0 TNF HLA-DRB1 CX3CL1
41 colitis 28.9 TNF MPO HLA-DRB1 CTLA4
42 skin disease 28.9 TNF FCGR2A CTLA4
43 lupus erythematosus 28.9 TNF HLA-DRB1 FCGR2A CTLA4
44 cholangitis 28.8 TNF MPO HLA-DRB1 CTLA4
45 central nervous system vasculitis 28.8 TNF MPO HLA-DRB1 CTLA4
46 asthma 28.1 TNF MPO HLA-DRB1 FCGR2A CTLA4
47 rheumatoid arthritis 27.5 TNF MPO HLA-DRB1 FCGR2A CX3CL1 CTLA4
48 systemic lupus erythematosus 27.5 TNF MPO HLA-DRB1 FCGR2A CX3CL1 CTLA4
49 glomerulonephritis 10.9
50 crescentic glomerulonephritis 10.6

Graphical network of the top 20 diseases related to Microscopic Polyangiitis:



Diseases related to Microscopic Polyangiitis

Symptoms & Phenotypes for Microscopic Polyangiitis

Human phenotypes related to Microscopic Polyangiitis:

58 31 (show all 38)
# Description HPO Frequency Orphanet Frequency HPO Source Accession
1 renal insufficiency 58 31 hallmark (90%) Very frequent (99-80%) HP:0000083
2 fever 58 31 hallmark (90%) Very frequent (99-80%) HP:0001945
3 skin rash 58 31 hallmark (90%) Very frequent (99-80%) HP:0000988
4 erythema 58 31 hallmark (90%) Very frequent (99-80%) HP:0010783
5 hematuria 58 31 hallmark (90%) Very frequent (99-80%) HP:0000790
6 autoimmunity 58 31 hallmark (90%) Very frequent (99-80%) HP:0002960
7 glomerulopathy 58 31 hallmark (90%) Very frequent (99-80%) HP:0100820
8 hemoptysis 58 31 hallmark (90%) Very frequent (99-80%) HP:0002105
9 vasculitis 58 31 hallmark (90%) Very frequent (99-80%) HP:0002633
10 oliguria 58 31 hallmark (90%) Very frequent (99-80%) HP:0100520
11 arthralgia 58 31 frequent (33%) Frequent (79-30%) HP:0002829
12 skin ulcer 58 31 frequent (33%) Frequent (79-30%) HP:0200042
13 nausea and vomiting 58 31 frequent (33%) Frequent (79-30%) HP:0002017
14 abdominal pain 58 31 frequent (33%) Frequent (79-30%) HP:0002027
15 gastrointestinal hemorrhage 58 31 frequent (33%) Frequent (79-30%) HP:0002239
16 myalgia 58 31 frequent (33%) Frequent (79-30%) HP:0003326
17 venous thrombosis 58 31 frequent (33%) Frequent (79-30%) HP:0004936
18 subcutaneous hemorrhage 58 31 frequent (33%) Frequent (79-30%) HP:0001933
19 gastrointestinal infarctions 58 31 frequent (33%) Frequent (79-30%) HP:0005244
20 diarrhea 58 31 frequent (33%) Frequent (79-30%) HP:0002014
21 peritonitis 58 31 frequent (33%) Frequent (79-30%) HP:0002586
22 arthritis 58 31 occasional (7.5%) Occasional (29-5%) HP:0001369
23 arrhythmia 58 31 occasional (7.5%) Occasional (29-5%) HP:0011675
24 sinusitis 58 31 occasional (7.5%) Occasional (29-5%) HP:0000246
25 subcutaneous nodule 58 31 occasional (7.5%) Occasional (29-5%) HP:0001482
26 congestive heart failure 58 31 occasional (7.5%) Occasional (29-5%) HP:0001635
27 pericarditis 58 31 occasional (7.5%) Occasional (29-5%) HP:0001701
28 gangrene 58 31 occasional (7.5%) Occasional (29-5%) HP:0100758
29 uveitis 58 31 occasional (7.5%) Occasional (29-5%) HP:0000554
30 paresthesia 58 31 occasional (7.5%) Occasional (29-5%) HP:0003401
31 epistaxis 58 31 occasional (7.5%) Occasional (29-5%) HP:0000421
32 cutis marmorata 58 31 occasional (7.5%) Occasional (29-5%) HP:0000965
33 pancreatitis 58 31 occasional (7.5%) Occasional (29-5%) HP:0001733
34 episcleritis 58 31 occasional (7.5%) Occasional (29-5%) HP:0100534
35 abnormal retinal vascular morphology 31 occasional (7.5%) HP:0008046
36 peripheral neuropathy 58 Occasional (29-5%)
37 abnormality of the retinal vasculature 58 Occasional (29-5%)
38 increased inflammatory response 58 Very frequent (99-80%)

Drugs & Therapeutics for Microscopic Polyangiitis

Drugs for Microscopic Polyangiitis (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 84)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Methotrexate Approved Phase 4 59-05-2, 1959-05-2 126941
2
leucovorin Approved Phase 4 58-05-9 6006 143
3
Mycophenolic acid Approved Phase 4 24280-93-1 446541
4
rituximab Approved Phase 4 174722-31-7 10201696
5
Methylprednisolone Approved, Vet_approved Phase 4 83-43-2 6741
6
Prednisolone phosphate Approved, Vet_approved Phase 4 302-25-0
7
Methylprednisolone hemisuccinate Approved Phase 4 2921-57-5
8 Prednisolone acetate Approved, Vet_approved Phase 4 52-21-1
9
Prednisolone Approved, Vet_approved Phase 4 50-24-8 5755
10
Hydroxychloroquine Approved Phase 4 118-42-3 3652
11
Povidone Approved Phase 4 9003-39-8
12
Folic acid Approved, Nutraceutical, Vet_approved Phase 4 59-30-3 6037
13
Prednisolone hemisuccinate Experimental Phase 4 2920-86-7
14 Dermatologic Agents Phase 4
15 Antimetabolites Phase 4
16 Folic Acid Antagonists Phase 4
17 Vitamin B Complex Phase 4
18 Folate Phase 4
19 Vitamin B9 Phase 4
20 Antitubercular Agents Phase 4
21 Anti-Bacterial Agents Phase 4
22 Antibiotics, Antitubercular Phase 4
23 glucocorticoids Phase 4
24 Methylprednisolone Acetate Phase 4
25 Hormones Phase 4
26 Antineoplastic Agents, Hormonal Phase 4
27 Hormone Antagonists Phase 4
28 Anti-Inflammatory Agents Phase 4
29 Tin Fluorides Phase 4
30 Anti-Infective Agents Phase 4
31 Antiparasitic Agents Phase 4
32 Antiprotozoal Agents Phase 4
33 Antimalarials Phase 4
34
belimumab Approved Phase 3 356547-88-1 10451420 5957
35
Azathioprine Approved Phase 3 446-86-6 2265
36
Clemastine Approved, Investigational Phase 3 15686-51-8 26987
37
Acetaminophen Approved Phase 3 103-90-2 1983
38
Granisetron Approved, Investigational Phase 3 109889-09-0 3510
39
Dexchlorpheniramine Experimental, Investigational Phase 3 25523-97-1 33036
40 Plasma Substitutes Phase 3
41 Gastrointestinal Agents Phase 2, Phase 3
42 Immunoglobulins, Intravenous Phase 3
43 Rho(D) Immune Globulin Phase 3
44 gamma-Globulins Phase 3
45 Immunoglobulin G Phase 3
46 Antiemetics Phase 2, Phase 3
47 Neuroprotective Agents Phase 2, Phase 3
48 Protective Agents Phase 2, Phase 3
49
Infliximab Approved Phase 2 170277-31-3
50
Prednisone Approved, Vet_approved Phase 2 53-03-2 5865

Interventional clinical trials:

(show top 50) (show all 69)
# Name Status NCT ID Phase Drugs
1 CHUSPAN PAN BP Treatment of Polyarteritis Nodosa and Microscopic Polyangiitis Without Poor-Prognosis Factors a Prospective Randomized Study in 125 Patients Unknown status NCT00400075 Phase 4 azathioprine;cyclophosphamide
2 Alemtuzumab for ANCA Associated Refractory Vasculitis - a Study of Safety and Efficacy Unknown status NCT01405807 Phase 4 Alemtuzumab
3 Treatment of Necrotizing Vasculitides for Patients Older Than 65 Years Comparison of Two Strategies Combining Steroids With or Without Immunosuppressants Completed NCT00307671 Phase 4 prednisone, methylprednisolone,cyclophosphamides;Cyclophosphamide, Azathioprine,prednisone,methylprednisolone;Mycophenolate mofetil,methotrexate
4 Short-Course Glucocorticoids and Rituximab in ANCA-Associated Vasculitis Completed NCT02169219 Phase 4 Glucocorticoids;Rituximab
5 Study Evaluating Rapid Infusion Rituximab in Patients With Autoimmune Diseases Completed NCT02040116 Phase 4 Rituximab Infusion
6 A Study Evaluating the Safety and Efficacy of Rituximab in Combination With Glucocorticoids in Participants With Wegener's Granulomatosis or Microscopic Polyangitis Recruiting NCT02115997 Phase 4 Methylprednisolone;Prednisone;Rituximab
7 Low-dose Glucocorticoids Plus Rituximab Versus High-dose Glucocorticoids Plus Rituximab for Remission Induction in ANCA-associated Vasculitis; a Multicentre, Open Label, Randomised Control Trial Active, not recruiting NCT02198248 Phase 4 Rituximab;Glucocorticoids
8 Hydroxychloroquine in ANCA Vasculitis Evaluation - A Multicentre, Randomised, Double-blind, Placebo-controlled Trial Not yet recruiting NCT04316494 Phase 4 Hydroxychloroquine;Placebo
9 Comparative Study of the Efficacy of Induction Therapy With Cyclophosphamide or Mycophenolate Mofetil for Non-Life-Threatening Relapses of PR3- or MPO-ANCA Associated Vasculitis Unknown status NCT00103792 Phase 3 mycophenolate mofetil;cyclophosphamide
10 Extended Follow Up of the Mainritsan 2 Study. Comparison Between a Long Term and a Conventional Maintenance Treatment With Rituximab: a Placebo- Controlled Randomized Trial Unknown status NCT02433522 Phase 3 rituximab;Placebo
11 Treatment of ANCA-Associated Vasculitides : Corticosteroids and Pulse Cyclophosphamide Followed by Maintenance Therapy With Methotrexate or Azathioprine: a Prospective Multicenter Randomized Trial Unknown status NCT00349674 Phase 3 Azathioprine: 2 mg/kg/day;methotrexate 0.3 mg/kg/week, to a maximum and optimal dose of 25 mg/week
12 A Phase 3, Multi-Center, Multinational, Randomized, Double-Blind, Study to Evaluate the Efficacy and Safety of Belimumab (HGS1006) in Combination With Azathioprine for the Maintenance of Remission in Wegener's Granulomatosis and Microscopic Polyangiitis Completed NCT01663623 Phase 3 Azathioprine
13 Evaluation of a New Treatment Strategy for Patients With Microscopic Polyangiitis, Polyarteritis Nodosa or Eosinophilic Granulomatosis With Polyangiitis (Churg Strauss Syndrome) Without Poor Prognosis Factors Completed NCT00647166 Phase 3 corticosteroid and azathioprine;corticosteroid and placebo
14 Plasma Exchange and Glucocorticoid Dosing in the Treatment of Anti-neutrophil Cytoplasm Antibody Associated Vasculitis: an International Randomized Controlled Trial Completed NCT00987389 Phase 3 Glucocorticoids [Standard Dose];Glucocorticoids [Reduced Dose]
15 Randomized Trial of Intravenous Pulse Versus Oral Continuous Cyclophosphamide for Induction of Remission in Systemic ANCA-Associated Vasculitides Completed NCT00430105 Phase 2, Phase 3 cyclophosphamide
16 Rituximab Therapy for the Induction of Remission and Tolerance in ANCA-Associated Vasculitis (ITN021AI) Completed NCT00104299 Phase 2, Phase 3 Rituximab plus cyclophosphamide placebo (rituximab group);Cyclophosphamide plus rituximab placebo (control group);Azathioprine;Methylprednisolone (or other glucocorticoid);Prednisone
17 MAINtenance of Remission Using RITuximab in Systemic ANCA-associated Vasculitis Completed NCT00748644 Phase 3 Rituximab;Azathioprine
18 An International, Open Label, Randomised Controlled Trial Comparing Rituximab With Azathioprine as Maintenance Therapy in Relapsing ANCA-associated Vasculitis Completed NCT01697267 Phase 3 Azathioprine
19 MAINtenance of Remission Using RITuximab in Systemic ANCA-associated Vasculitis II Completed NCT01731561 Phase 3 Rituximab (Arm B);Rituximab (Arm A)
20 Evaluation of Rituximab-based Regimen Compared to Conventional Therapeutic Strategy For Remission Induction In Patients With Newly-Diagnosed or Relapsing Eosinophilic Granulomatosis With Polyangiitis. Prospective, Randomized, Controlled, Double-blind Study Recruiting NCT02807103 Phase 3 Rituximab;Placebo-rituximab;Cyclophosphamide;Placebo-cyclophosphamide
21 Evaluating Favorable, Immunological Effects of Rituximab With Cyclophosphamide Compared to Rituximab Alone in AAV Patients Recruiting NCT03942887 Phase 3 Rituximab;endoxan;Methylprednisolone;Prednisolone
22 Efficacy and Safety of Rituximab in the Treatment of Good Prognosis Microscopic Polyangiitis Not yet recruiting NCT03920722 Phase 3 Rituximab;placebo
23 Intravenous Immunoglobulin After Relapse in Vasculitis (Microscopic Polyangiitis, Wegener’s Granulomatosis and SHURG-STRAUSS Syndrome) During and After Corticosteroids and Immunosuppressant Therapies a Multicenter Prospective Trial Terminated NCT00307658 Phase 3 Intravenous immunoglobulins (human immunoglobulins G)
24 Mycophenolate Mofetil Versus Azathioprine for Maintenance Therapy in ANCA Associated Systemic Vasculitis Terminated NCT00307645 Phase 3 Cyclophosphamide;Mycophenolate mofetil;Azathioprine;Prednisone (and methylprednisolone)
25 Randomised Trial of Plasma Exchange or High Dose Methyl Prednisolone as Adjunctive Therapy for Severe Renal Vasculitis Terminated NCT01408836 Phase 2, Phase 3 Intravenous methyl prednisolone;Methyl prednisolone
26 Cyclophosphamide Versus Methotrexate for Remission Maintenance in Systemic Necrotizing Vasculitides. A Randomized Controlled Trial. Unknown status NCT00751517 Phase 2 Methotrexate;Cyclophosphamide
27 A Phase IIA, International, Multicenter, Open-label, Uncontrolled Study to Evaluate The Safety And Pharmacokinetics of 4 × 375 mg/m2 Intravenous Rituximab in Pediatric Patients With Severe Granulomatosis With Polyangiitis (Wegener's) or Microscopic Polyangiitis Completed NCT01750697 Phase 2 Rituximab
28 Phase II Pilot Cohort Study to Investigate the Safety and Efficacy of Infliximab as Additional Therapy in the Treatment if Anti-Neutrophil Cytoplasm Antibody Associated Vasculitis Completed NCT00753103 Phase 2 Cyclophosphamide;Prednisolone;Azathioprine;Mycophenolate mofetil;Methylprednisolone
29 An Open Trial of the Efficacy of Glucocorticoids and Methotrexate (MTX) in the Treatment of Systemic Vasculitis Completed NCT00001256 Phase 2 prednisone and methotrexate
30 A Randomized, Double-blind, Double-dummy, Active-controlled, Multicenter, 2-part Phase II Study on Replacement of Steroids by IFX-1 in Active Granulomatosis With Polyangiitis (GPA) and Microscopic Polyangiitis (MPA) Recruiting NCT03895801 Phase 2 IFX-1;Placebo-IFX-1;Glucocorticoid (GC);Placebo-Glucocorticoid (Placebo-GC)
31 Low Dose Naltrexone to Improve Physical Health in Patients With Vasculitis Recruiting NCT03482479 Phase 2 Naltrexone Hydrochloride
32 A Pilot Study to Evaluate the Efficacy and Safety of Pirfenidone in Patients With Pulmonary Fibrosis With Anti-myeloperoxydase (MPO) Antibodies or With Anti-MPO Associated Vasculitis." Recruiting NCT03385668 Phase 2 Pirfenidone
33 Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Phase II Efficacy and Safety Study of IFX-1 in Add-On to Standard of Care in Granulomatosis With Polyangiitis (GPA) and Microscopic Polyangiitis (MPA) Active, not recruiting NCT03712345 Phase 2 IFX-1;IFX-1;Placebo
34 A Pilot Study Examining the Effect of Abatacept in ANCA Associated Vasculitis Terminated NCT00482066 Phase 2 Abatacept (Orencia)
35 A Randomized, Double-Blind, Placebo-Controlled Trial to Evaluate the Efficacy, Safety, and Tolerability of Blisibimod in Addition to Methotrexate During Induction of Remission in Subjects With ANCA-Associated Small Vessel Vasculitis Withdrawn NCT01598857 Phase 2 Blisibimod;Placebo
36 A Pilot Study of Mycophenolate Mofetil (MMF) in Patients With p-ANCA Microscopic Polyangiitis and Mild to Moderate Renal Dysfunction. Completed NCT00405860 Phase 1 CellCept (mycophenolate mofetil)
37 High Dose Immune Suppression With Hematopoietic Stem Cell Support in Refractory Vasculitis, Necrotizing Vasculitis, Neurovascular Behcet's Disease, and Sjogren's Syndrome Terminated NCT00278512 Phase 1 Cyclophosphamide;ATG (rabbit);G-CSF;Campath-1h;Fludarabine;Tacrolimus;Mesna
38 Cohort Study of Chinese Patients With Pulmonary Vasculitis Unknown status NCT02126098
39 A Qualitative Study Using Interviews With Patients Who Have Anti-neutrophil Cytoplasm Antibody (ANCA) Associated Vasculitis, to Develop a Patient Reported Outcome (PRO) Measure Unknown status NCT01729624
40 ACR/EULAR Endorsed Study to Develop New Diagnostic and Classification Criteria for Primary Systemic Vasculitis Unknown status NCT01066208
41 Chronic Childhood Vasculitis: Characterizing the Individual Rare Diseases to Improve Patient Outcomes Unknown status NCT02006134
42 Eosinophilic Granulomatosis With Polyangiitis Cohort Unknown status NCT03036670
43 Neutrophils Function and Identification of Prognostic Factors in Granulomatosis With Polyangiitis (Formerly Named Wegener's Granulomatosis). Unknown status NCT01862068
44 Infliximab Versus Rituximab in Systemic Necrotizing Vasculitides With Positive ANCA After Relapse or Resistant Immunosuppressant Therapies Completed NCT00307593 Infliximab;Rituximab
45 Prospective, Observational Safety Study of Patients With Granulomatosis With Polyangiitis (Wegener's) or Microscopic Polyangiitis Treated With Rituximab Completed NCT01613599 Rituximab
46 Reproductive Health in Men and Women With Vasculitis Completed NCT02176070
47 VCRC Validation of Patient-Reported Diagnostic Data Completed NCT02190942
48 Educational Needs of Patients With Systemic Vasculitis- an International Survey Completed NCT02190929
49 Illness Perception, Fatigue, and Function in Systemic Vasculitis (The VCRC Vasculitis Perception (VIP) Study) Completed NCT02190916
50 The Journey of Patients With Vasculitis From First Symptom to Diagnosis Completed NCT03410290

Search NIH Clinical Center for Microscopic Polyangiitis

Genetic Tests for Microscopic Polyangiitis

Anatomical Context for Microscopic Polyangiitis

MalaCards organs/tissues related to Microscopic Polyangiitis:

40
Neutrophil, Lung, Kidney, Skin, Testes, Endothelial, T Cells

Publications for Microscopic Polyangiitis

Articles related to Microscopic Polyangiitis:

(show top 50) (show all 1807)
# Title Authors PMID Year
1
Hyperuricemia is associated with decreased renal function and occurrence of end-stage renal disease in patients with microscopic polyangiitis and granulomatosis with polyangiitis: a retrospective study. 61
32314011 2020
2
Thai Patients With Antineutrophil Cytoplasmic Antibody-Associated Vasculitis: Outcomes and Risk Factors for Mortality. 61
32568951 2020
3
Lingual and digital necrosis in microscopic polyangiitis. 61
32500149 2020
4
Periodic fever syndromes: a patient diagnosed with recurrent Kawasaki disease. 61
32524933 2020
5
Splenic infarction is not rare in granulomatosis with polyangiitis. 61
32107662 2020
6
Demographic and clinical characteristics of patients with ANCA-positive vasculitis in a Colombian University Hospital over a 12-year period: 2005-2017. 61
32564160 2020
7
An increased disease burden of autoimmune inflammatory rheumatic diseases in Korea. 61
31852583 2020
8
Comprehensive meta-analysis reveals an association of the HLA-DRB1*1602 allele with autoimmune diseases mediated predominantly by autoantibodies. 61
32234402 2020
9
Long-Term Rituximab Use to Maintain Remission of Antineutrophil Cytoplasmic Antibody-Associated Vasculitis: A Randomized Trial. 61
32479166 2020
10
Favorable efficacy of rituximab in ANCA-associated vasculitis patients with excessive B cell differentiation. 61
32539843 2020
11
Orbital Microscopic Polyangiitis With Secondary Angle Closure Due to Uveal Effusion. 61
32433349 2020
12
Plasma exosomal miRNAs involved in endothelial injury in microscopic polyangiitis patients. 61
32232900 2020
13
Long-Term Safety of Rituximab in Granulomatosis with Polyangiitis or Microscopic Polyangiitis. 61
32475029 2020
14
Biologic therapy in severe and refractory peripheral ulcerative keratitis (PUK). Multicenter study of 34 patients. 61
32497929 2020
15
An update on the epidemiology of ANCA-associated vasculitis. 61
32348522 2020
16
Cutaneous manifestations of anti-neutrophil cytoplasmic antibody-associated vasculitis. 61
32419292 2020
17
Clinical Characteristics of an Internet-Based Cohort of Patients with a Self-Reported Diagnosis of Granulomatosis with Polyangiitis or Microscopic Polyangiitis: Observational Study. 61
32459634 2020
18
Treatment of Granulomatosis with Polyangiitis and Microscopic Polyangiitis: Should Type of ANCA Guide the Treatment? 61
32471814 2020
19
Microscopic polyangiitis: Clinical characteristics and long-term outcomes of 378 patients from the French Vasculitis Study Group Registry. 61
32340774 2020
20
Complement profile in microscopic polyangiitis and granulomatosis with polyangiitis: analysis using sera from a nationwide prospective cohort study. 61
32286129 2020
21
Effect of Treatment on Damage and Hospitalization in Elderly Patients with Microscopic Polyangiitis and Granulomatosis with Polyangiitis. 61
31308208 2020
22
Plasma Exchange Therapy to Reduce Mortality in Japanese Patients With Diffuse Alveolar Hemorrhage and Microscopic Polyangiitis. 61
31233282 2020
23
Clinical associations of renal involvement in ANCA-associated vasculitis. 61
32068190 2020
24
Distinct HLA and non-HLA associations in different subtypes of ANCA-associated vasculitides in North India. 61
32297471 2020
25
Value of Prognostic Scores in Anti-Neutrophil Cytoplasmic Antibody (ANCA) Associated Vasculitis Patients in Intensive Care Unit: A Multicenter Retrospective Cohort Study from Turkey 61
32304194 2020
26
Association between preexisting lung involvements and the risk of diffuse alveolar hemorrhage in patients with microscopic polyangiitis: A multi-center retrospective cohort study. 61
30929541 2020
27
Renal involvement at baseline can predict major renal relapse in anti-neutrophil cytoplasmic antibody (ANCA)-associated vasculitis. 61
32441648 2020
28
Prevalence and Risk Factors for Major Infections in Patients with Antineutrophil Cytoplasmic Antibody-associated Vasculitis: Influence on the Disease Outcome. 61
31203229 2020
29
Interstitial Lung Disease in Antineutrophil Cytoplasmic Antibody-Associated Vasculitis Patients: Comparison With Idiopathic Pulmonary Fibrosis. 61
32251058 2020
30
[Targeted therapies for connective tissue diseases and vasculitis]. 61
32167250 2020
31
Epidemiology and management of interstitial lung disease in ANCA-associated vasculitis. 61
32324122 2020
32
Treatment and its side effects in ANCA-associated vasculitides - Study based on POLVAS registry data. 61
31958704 2020
33
Significant association between clinical characteristics and immuno-phenotypes in patients with ANCA-associated vasculitis. 61
31377799 2020
34
Induction of hemodialysis with an arteriovenous fistula in a patient with hemophilia A. 61
32180153 2020
35
An overlap of antineutrophil cytoplasmic antibody (ANCA)-associated glomerulonephritis and IgG4-related kidney disease. 61
31805271 2020
36
Disease and treatment-related morbidity in young and elderly patients with granulomatosis with polyangiitis and microscopic polyangiitis. 61
32173060 2020
37
Childhood GPA, EGPA, and MPA. 61
31837445 2020
38
Anti-Neutrophil Cytoplasmic Antibody-Associated Ocular Manifestations in Japan: A Review of 18 Patients. 61
32078414 2020
39
Rituximab utilization for approved and off-label nononcology indications and patients' experiences with the Patient Alert Card. 61
31911839 2020
40
Microscopic Polyangiitis With Selective Involvement of Central and Peripheral Nervous System: A Case Report. 61
32411070 2020
41
No evident association of nasal carriage of Staphylococcus aureus or its small-colony variants with cotrimoxazole use or ANCA-associated vasculitis relapses. 61
31834404 2020
42
Rationale of concomitant cyclophosphamide for remission-induction in patients with antineutrophil cytoplasmic antibody-associated vasculitis: A propensity score-matched analysis of two nationwide prospective cohort studies. 61
31859544 2020
43
Clinical implication of chronic paranasal sinusitis for the classification of microscopic polyangiitis. 61
31573728 2020
44
Microscopic Polyangiitis Initially Presumed to Be Endocarditis. 61
32257454 2020
45
Vasculitis and the ear: a literature review. 61
31599796 2020
46
Pathophysiology of ANCA-associated vasculitis. 61
32493021 2020
47
Temporal Arteritis and Vision Loss in Microscopic Polyangiitis: A Case Report and Literature Review. 61
32274229 2020
48
Usual interstitial pneumonia in ANCA-associated vasculitis: A poor prognostic factor. 61
31570253 2020
49
Predictors of renal outcomes in anti-neutrophil cytoplasmic antibody glomerulonephritis. 61
32129212 2020
50
Palisaded Neutrophilic and Granulomatous Dermatitis in a Patient with Granulomatosis with Polyangiitis. 61
32308576 2020

Variations for Microscopic Polyangiitis

Expression for Microscopic Polyangiitis

Search GEO for disease gene expression data for Microscopic Polyangiitis.

Pathways for Microscopic Polyangiitis

GO Terms for Microscopic Polyangiitis

Cellular components related to Microscopic Polyangiitis according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 integral component of plasma membrane GO:0005887 9.26 TNF HLA-DRB1 FCGR2A CTLA4
2 external side of plasma membrane GO:0009897 8.8 TNF HLA-DRB1 CTLA4

Biological processes related to Microscopic Polyangiitis according to GeneCards Suite gene sharing:

(show all 11)
# Name GO ID Score Top Affiliating Genes
1 positive regulation of ERK1 and ERK2 cascade GO:0070374 9.5 TNF HLA-DRB1 CX3CL1
2 positive regulation of smooth muscle cell proliferation GO:0048661 9.49 TNF CX3CL1
3 negative regulation of T cell proliferation GO:0042130 9.48 HLA-DRB1 CTLA4
4 negative regulation of extrinsic apoptotic signaling pathway in absence of ligand GO:2001240 9.46 TNF CX3CL1
5 negative regulation of interleukin-6 production GO:0032715 9.43 TNF CX3CL1
6 positive regulation of I-kappaB kinase/NF-kappaB signaling GO:0043123 9.43 TNF HLA-DRB1 CX3CL1
7 negative regulation of apoptotic signaling pathway GO:2001234 9.4 TNF CX3CL1
8 microglial cell activation GO:0001774 9.37 TNF CX3CL1
9 defense response GO:0006952 9.33 TNF MPO CX3CL1
10 immune response GO:0006955 9.26 TNF HLA-DRB1 CX3CL1 CTLA4
11 positive regulation of I-kappaB phosphorylation GO:1903721 8.62 TNF CX3CL1

Sources for Microscopic Polyangiitis

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 EFO
18 ExPASy
19 FMA
28 GO
29 GTR
30 HMDB
31 HPO
32 ICD10
33 ICD10 via Orphanet
34 ICD9CM
35 IUPHAR
36 KEGG
37 LifeMap
39 LOVD
41 MedGen
43 MeSH
44 MESH via Orphanet
45 MGI
48 NCI
49 NCIt
50 NDF-RT
53 NINDS
54 Novoseek
56 OMIM
57 OMIM via Orphanet
61 PubMed
63 QIAGEN
68 SNOMED-CT via HPO
69 TGDB
70 Tocris
71 UMLS
72 UMLS via Orphanet
Content
Loading form....